Malarone Paediatric

Proguanil hydrochloride and atovaquone, the active ingredients in Malarone Paediatric, are antimalarial agents presented as an oral paediatric formulation for oral use. They prevent malaria infection and treat acute uncomplicated malaria in children and adolescents.

GNH USA supplies Malarone Paediatric as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone Paediatric, a combination antimalarial, is indicated for the following malaria‑related conditions.

- Prevention of malaria infection: provides prophylactic protection for children traveling to or residing in malaria‑endemic areas. - Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears infection in pediatric patients with confirmed P. falciparum malaria. - Treatment of acute uncomplicated malaria caused by chloroquine‑resistant Plasmodium species: effective against resistant strains in children.

Common side effects are generally mild and reversible.

Common Side Effects: - Nausea - Abdominal pain - Headache - Vomiting - Loss of appetite - Diarrhoea - Rash

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction or elevated transaminases - Hemolytic anaemia in patients with G6PD deficiency - Severe neutropenia or agranulocytosis - Anaphylactic or severe hypersensitivity reactions

Malarone Paediatric should be used with attention to specific safety considerations.

- Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: consider possible exposure to infant; discuss with healthcare provider. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Malarone Paediatric may interact with several medicines; classification guides monitoring.

Major Interactions (Avoid): - Rifampicin: markedly reduces plasma concentrations of both components, compromising efficacy. - Protease inhibitors (e.g., ritonavir): may increase atovaquone levels, raising risk of toxicity. - Strong CYP2C19 inhibitors (e.g., fluconazole): can elevate proguanil concentrations.

Moderate Interactions (Monitor Closely): - Phenytoin: may lower atovaquone exposure, reducing effectiveness. - Barbiturates: can decrease drug levels, necessitating efficacy monitoring. - Macrolide antibiotics (e.g., erythromycin): may increase atovaquone concentrations, requiring observation for adverse effects.